Metabolic · Body Composition · Cardiovascular

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

A dual GIP and GLP-1 receptor agonist with FDA approvals across type 2 diabetes, chronic weight management, and obstructive sleep apnea in obesity.

Sign in to add to watchlist

Evidence strength

Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.

ARelatively Stronger Human Evidence

Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.

Key Takeaways

  • ›Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist with a large Phase 3 evidence base.
  • ›It is FDA-approved for type 2 diabetes, weight management, and obesity-related obstructive sleep apnea.
  • ›In a head-to-head trial it outperformed semaglutide on weight and blood sugar at the doses tested.
  • ›Gastrointestinal side effects are most common; weight tends to return after stopping.
  • ›It is a prescription medicine. Work with a licensed healthcare professional on any treatment decision.

What It Is

Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is fatty-acid acylated to bind albumin, which extends its plasma half-life enough to support once-weekly administration. Eli Lilly developed the molecule as a successor concept to selective GLP-1 agonists, with the dual-agonist hypothesis being that adding GIP activity could enhance metabolic effects beyond what GLP-1 agonism alone produces.

Mechanistically, GLP-1 receptor activation enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central pathways. GIP receptor activation contributes additional insulinotropic effects and appears to modulate adipose tissue handling of nutrients. The relative contributions of each arm in humans remain an active area of investigation.

Unlock the full Tirzepatide research report

Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 5 cited sources.

Get Vial+ — $20 one-time

Lifetime access · the community forum stays free.

Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.